Minerva Neurosciences | NERV - Interest Expense On Debt


Minerva Neurosciences reported $2.31M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Adma Biologics USD 2.1M 474K Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cipla INR 131.3M 9M Mar/2026
Compugen USD 1.35M 399K Mar/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Takeda JPY 43.65B 79.98B Mar/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025